ATM is altered in 5.76% of prostate carcinoma patients [3].

ATM is an inclusion criterion in 23 clinical trials for prostate carcinoma, of which 19 are open and 4 are closed. Of the trials that contain ATM status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 14 are phase 2 (12 open), and 2 are phase 3 (2 open) [4].

Olaparib has evidence of efficacy in patients with ATM mutation in prostate carcinoma [4].

ATM is altered in 5.8% of malignant solid tumor patients [3].

ATM is an inclusion criterion in 45 clinical trials for malignant solid tumor, of which 37 are open and 8 are closed. Of the trials that contain ATM status and malignant solid tumor as inclusion criteria, 18 are phase 1 (13 open), 8 are phase 1/phase 2 (5 open), and 19 are phase 2 (19 open) [4].

ATM is altered in 3.53% of breast carcinoma patients [3].

ATM is an inclusion criterion in 26 clinical trials for breast carcinoma, of which 20 are open and 6 are closed. Of the trials that contain ATM status and breast carcinoma as inclusion criteria, 8 are phase 1 (5 open), 4 are phase 1/phase 2 (3 open), 12 are phase 2 (10 open), and 2 are phase 3 (2 open) [4].

ATM is altered in 5.73% of prostate adenocarcinoma patients [3].

ATM is an inclusion criterion in 20 clinical trials for prostate adenocarcinoma, of which 18 are open and 2 are closed. Of the trials that contain ATM status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 17 are phase 2 (15 open), and 2 are phase 3 (2 open) [4].

ATM is altered in 4.06% of ovarian carcinoma patients [3].

ATM is an inclusion criterion in 20 clinical trials for ovarian carcinoma, of which 15 are open and 5 are closed. Of the trials that contain ATM status and ovarian carcinoma as inclusion criteria, 6 are phase 1 (4 open), 4 are phase 1/phase 2 (3 open), 8 are phase 2 (7 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [4].

ATM is altered in 7.14% of non-small cell lung carcinoma patients [3].

ATM is an inclusion criterion in 10 clinical trials for non-small cell lung carcinoma, of which 7 are open and 3 are closed. Of the trials that contain ATM status and non-small cell lung carcinoma as inclusion criteria, 3 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [4].

ATM is altered in 4.35% of primary peritoneal carcinoma patients [3].

ATM is an inclusion criterion in 10 clinical trials for primary peritoneal carcinoma, of which 7 are open and 3 are closed. Of the trials that contain ATM status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [4].

ATM is an inclusion criterion in 9 clinical trials for fallopian tube carcinoma, of which 6 are open and 3 are closed. Of the trials that contain ATM status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [4].

ATM is altered in 5.26% of adenocarcinoma of the gastroesophageal junction patients [3].

ATM is an inclusion criterion in 8 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 7 are open and 1 is closed. Of the trials that contain ATM status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [4].

ATM is altered in 4.2% of pancreatic adenocarcinoma patients [3].

ATM is an inclusion criterion in 7 clinical trials for pancreatic adenocarcinoma, of which 6 are open and 1 is closed. Of the trials that contain ATM status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (5 open) [4].

ATM is altered in 10.7% of urothelial carcinoma patients [3].

ATM is an inclusion criterion in 6 clinical trials for urothelial carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ATM status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 5 are phase 2 (5 open) [4].

ATM is altered in 4.18% of pancreatic carcinoma patients [3].

ATM is an inclusion criterion in 6 clinical trials for pancreatic carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ATM status and pancreatic carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 4 are phase 2 (4 open) [4].

ATM is altered in 3.75% of small cell lung carcinoma patients [3].

ATM is an inclusion criterion in 6 clinical trials for small cell lung carcinoma, of which 3 are open and 3 are closed. Of the trials that contain ATM status and small cell lung carcinoma as inclusion criteria, 2 are phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [4].

ATM is altered in 7.51% of colorectal carcinoma patients [3].

ATM is an inclusion criterion in 5 clinical trials for colorectal carcinoma, of which 3 are open and 2 are closed. Of the trials that contain ATM status and colorectal carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [4].

ATM is altered in 6.99% of gastric carcinoma patients [3].

ATM is an inclusion criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain ATM status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].

ATM is altered in 6.84% of gastric adenocarcinoma patients [3].

ATM is an inclusion criterion in 5 clinical trials for gastric adenocarcinoma, of which 5 are open and 0 are closed. Of the trials that contain ATM status and gastric adenocarcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 3 are phase 2 (3 open) [4].

ATM is altered in 6.87% of melanoma patients [3].

ATM is an inclusion criterion in 5 clinical trials for melanoma, of which 4 are open and 1 is closed. Of the trials that contain ATM status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (4 open) [4].

ATM is altered in 11.39% of endometrial carcinoma patients [3].

ATM is an inclusion criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ATM status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

ATM is altered in 7.97% of non-hodgkin lymphoma patients [3].

ATM is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain ATM status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [4].

ATM is altered in 5.29% of cervical carcinoma patients [3].

ATM is an inclusion criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATM status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

ATM is altered in 4.14% of head and neck carcinoma patients [3].

ATM is an inclusion criterion in 4 clinical trials for head and neck carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATM status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

ATM is altered in 2.52% of soft tissue sarcoma patients [3].

ATM is an inclusion criterion in 4 clinical trials for soft tissue sarcoma, of which 3 are open and 1 is closed. Of the trials that contain ATM status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

ATM is altered in 10.67% of bladder carcinoma patients [3].

ATM is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ATM status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [4].

ATM is altered in 4.43% of clear cell renal cell carcinoma patients [3].

ATM is an inclusion criterion in 3 clinical trials for clear cell renal cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ATM status and clear cell renal cell carcinoma as inclusion criteria, 3 are phase 2 (3 open) [4].

ATM is altered in 4.45% of head and neck squamous cell carcinoma patients [3].

ATM is an inclusion criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ATM status and head and neck squamous cell carcinoma as inclusion criteria, 3 are phase 1/phase 2 (2 open) [4].

ATM is altered in 3.61% of high grade ovarian serous adenocarcinoma patients [3].

ATM is an inclusion criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain ATM status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [4].

ATM is altered in 11.08% of bladder urothelial carcinoma patients [3].

ATM is an inclusion criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ATM status and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

ATM is altered in 6.6% of lymphoma patients [3].

ATM is an inclusion criterion in 2 clinical trials for lymphoma, of which 1 is open and 1 is closed. Of the trials that contain ATM status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

ATM is altered in 4.98% of squamous cell lung carcinoma patients [3].

ATM is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ATM status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [4].

ATM is altered in 4.49% of malignant central nervous system neoplasm patients [3].

ATM is an inclusion criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain ATM status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

ATM is altered in 4.55% of multiple myeloma patients [3].

ATM is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain ATM status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [4].

ATM is altered in 3.87% of esophageal carcinoma patients [3].

ATM is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ATM status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

ATM is altered in 3.9% of esophageal adenocarcinoma patients [3].

ATM is an inclusion criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ATM status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

ATM is altered in 2.42% of osteosarcoma patients [3].

ATM is an inclusion criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain ATM status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

ATM is altered in 2.49% of gastrointestinal stromal tumor patients [3].

ATM is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain ATM status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

ATM is altered in 41.9% of mantle cell lymphoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATM is altered in 41.67% of prolymphocytic leukemia patients [3].

ATM is an inclusion criterion in 1 clinical trial for prolymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ATM status and prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is altered in 14.29% of vaginal carcinoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATM status and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

ATM is altered in 13.68% of malignant small intestinal neoplasm patients [3].

ATM is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATM status and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ATM is altered in 8.86% of malignant uterine neoplasm patients [3].

ATM is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATM status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is altered in 8.97% of B-cell non-hodgkin lymphoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is altered in 7.7% of malignant intestinal neoplasm patients [3].

ATM is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATM status and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ATM is altered in 7.49% of colorectal adenocarcinoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ATM is altered in 7.0% of lung carcinoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is altered in 6.99% of malignant gastric neoplasm patients [3].

ATM is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATM status and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ATM is altered in 6.07% of gallbladder carcinoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is altered in 5.71% of pancreatic ductal adenocarcinoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATM status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

ATM is altered in 6.18% of ampulla of vater carcinoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ATM is altered in 5.46% of medulloblastoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATM is altered in 5.88% of biliary tract carcinoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is altered in 5.83% of bile duct adenocarcinoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ATM is altered in 5.83% of bile duct carcinoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is altered in 5.83% of cholangiocarcinoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is altered in 5.67% of cancer patients [3].

ATM is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains ATM status and cancer as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is altered in 5.35% of malignant esophagogastric neoplasm patients [3].

ATM is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATM status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ATM is altered in 5.15% of glioblastoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains ATM status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ATM is altered in 4.54% of renal cell carcinoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is altered in 4.59% of malignant mesothelioma patients [3].

ATM is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is altered in 4.54% of glioma patients [3].

ATM is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATM is altered in 4.64% of mature T-cell and NK-cell non-hodgkin lymphoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATM is altered in 4.48% of anal carcinoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATM status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

ATM is altered in 4.23% of malignant ovarian epithelial tumor patients [3].

ATM is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains ATM status and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ATM is altered in 4.01% of leiomyosarcoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is altered in 3.57% of penile carcinoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATM status and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

ATM is altered in 3.38% of esophageal squamous cell carcinoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is altered in 3.77% of diffuse large B-cell lymphoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATM is altered in 3.02% of anaplastic astrocytoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains ATM status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ATM is altered in 3.44% of invasive breast carcinoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is altered in 2.97% of sarcoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ATM status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ATM is altered in 3.2% of neuroblastoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATM is altered in 2.39% of low grade ovarian serous adenocarcinoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATM is altered in 1.93% of myelodysplastic syndromes patients [3].

ATM is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains ATM status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is altered in 1.87% of acute myeloid leukemia patients [3].

ATM is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ATM status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is altered in 1.23% of chronic myeloid leukemia patients [3].

ATM is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ATM status and chronic myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is altered in 1.06% of langerhans cell histiocytosis patients [3].

ATM is an inclusion criterion in 1 clinical trial for langerhans cell histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains ATM status and langerhans cell histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is altered in 0.49% of rhabdomyosarcoma patients [3].

ATM is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATM is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ATM status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ATM status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATM is an inclusion criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATM is an inclusion criterion in 1 clinical trial for histiocytic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and histiocytic sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is an inclusion criterion in 1 clinical trial for juvenile xanthogranuloma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and juvenile xanthogranuloma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATM is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATM is an inclusion criterion in 1 clinical trial for primary peritoneal high grade serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and primary peritoneal high grade serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATM is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATM status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].